Hepatic Encephalopathy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hepatic encephalopathy. 17 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
17
Active US patents
66/100
Avg vulnerability
$1.5B
Annual revenue covered

Originators in Hepatic Encephalopathy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 17 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hepatic encephalopathy. Each bar = one year. Y-axis scaled to peak year (15 patents).

2
27
15
29

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xifaxan
rifaximin
 Bausch Health 17 66 $1.5B 2027-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11779571 Xifaxan method of use 83 2029-02-26
11564912 Xifaxan method of use 83 2029-02-26
8193196 Xifaxan method of use 80 2027-09-02
10765667 Xifaxan method of use 75 2029-02-26
10456384 Xifaxan method of use 75 2029-02-26
8829017 Xifaxan method of use 73 2029-07-24
7928115 Xifaxan method of use 73 2029-07-24
8642573 Xifaxan method of use 73 2029-10-02
8309569 Xifaxan method of use 68 2029-07-18
10314828 Xifaxan method of use 68 2029-07-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8193196 Xifaxan composition of matter 22 2027-09-02
8969398 Xifaxan method of use 68 2029-10-02
10709694 Xifaxan method of use 68 2029-07-24
10314828 Xifaxan method of use 68 2029-07-24
9421195 Xifaxan method of use 68 2029-07-24
8946252 Xifaxan method of use 68 2029-07-24
9629828 Xifaxan method of use 68 2029-07-24
10335397 Xifaxan method of use 68 2029-07-24
8309569 Xifaxan method of use 68 2029-07-18
8642573 Xifaxan method of use 73 2029-10-02

Related